JP2008501800A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008501800A5 JP2008501800A5 JP2007527597A JP2007527597A JP2008501800A5 JP 2008501800 A5 JP2008501800 A5 JP 2008501800A5 JP 2007527597 A JP2007527597 A JP 2007527597A JP 2007527597 A JP2007527597 A JP 2007527597A JP 2008501800 A5 JP2008501800 A5 JP 2008501800A5
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- hydroxy
- methyl
- trifluoro
- phenylbutanamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Perfluoro Chemical group 0.000 claims 32
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 11
- SEXSZNASUHPUPT-OAHLLOKOSA-N (2r)-3,3,3-trifluoro-n-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hydroxy-2-phenylpropanamide Chemical compound CC1=CN=C(F)C(CNC(=O)[C@](O)(C=2C=CC=CC=2)C(F)(F)F)=C1 SEXSZNASUHPUPT-OAHLLOKOSA-N 0.000 claims 6
- YSMGNNKNGUPHCD-OAHLLOKOSA-N (2r)-3,3,3-trifluoro-n-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-hydroxy-2-phenylpropanamide Chemical compound O=C([C@](O)(C=1C=CC=CC=1)C(F)(F)F)NCC1=CC(C(F)(F)F)=CC=C1F YSMGNNKNGUPHCD-OAHLLOKOSA-N 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- UAJUEDTYIVUMKP-GOSISDBHSA-N (2r)-n-[(5-cyclopropyl-2-fluorophenyl)methyl]-3,3,3-trifluoro-2-(4-fluorophenyl)-2-hydroxypropanamide Chemical compound O=C([C@](O)(C=1C=CC(F)=CC=1)C(F)(F)F)NCC(C(=CC=1)F)=CC=1C1CC1 UAJUEDTYIVUMKP-GOSISDBHSA-N 0.000 claims 3
- USHFGOGPBYRMNY-OAHLLOKOSA-N (2r)-n-[[3-bromo-2-fluoro-5-(trifluoromethyl)phenyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-phenylpropanamide Chemical compound O=C([C@](O)(C=1C=CC=CC=1)C(F)(F)F)NCC1=CC(C(F)(F)F)=CC(Br)=C1F USHFGOGPBYRMNY-OAHLLOKOSA-N 0.000 claims 3
- UAJUEDTYIVUMKP-SFHVURJKSA-N (2s)-n-[(5-cyclopropyl-2-fluorophenyl)methyl]-3,3,3-trifluoro-2-(4-fluorophenyl)-2-hydroxypropanamide Chemical compound O=C([C@@](O)(C=1C=CC(F)=CC=1)C(F)(F)F)NCC(C(=CC=1)F)=CC=1C1CC1 UAJUEDTYIVUMKP-SFHVURJKSA-N 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- JNDQWCQWQFGZGJ-SFHVURJKSA-N (2r)-2-cyclopropyl-n-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hydroxy-2-phenylacetamide Chemical compound CC1=CN=C(F)C(CNC(=O)[C@@](O)(C2CC2)C=2C=CC=CC=2)=C1 JNDQWCQWQFGZGJ-SFHVURJKSA-N 0.000 claims 2
- JNDQWCQWQFGZGJ-GOSISDBHSA-N (2s)-2-cyclopropyl-n-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hydroxy-2-phenylacetamide Chemical compound CC1=CN=C(F)C(CNC(=O)[C@](O)(C2CC2)C=2C=CC=CC=2)=C1 JNDQWCQWQFGZGJ-GOSISDBHSA-N 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 229940122361 Bisphosphonate Drugs 0.000 claims 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000002917 arthritic effect Effects 0.000 claims 2
- 150000004663 bisphosphonates Chemical class 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 229940011871 estrogen Drugs 0.000 claims 2
- 239000000262 estrogen Substances 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 210000002997 osteoclast Anatomy 0.000 claims 2
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 claims 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 2
- 150000003721 vitamin K derivatives Chemical class 0.000 claims 2
- XSJFQSRYOWBLNY-QGZVFWFLSA-N (2r)-2-(3-chlorophenyl)-n-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-hydroxybutanamide Chemical compound O=C([C@@](O)(CC)C=1C=C(Cl)C=CC=1)NCC1=CC(C(F)(F)F)=CC=C1F XSJFQSRYOWBLNY-QGZVFWFLSA-N 0.000 claims 1
- HNNCNBYDSNFDDX-OAHLLOKOSA-N (2r)-2-(4-chloro-3-fluorophenyl)-3,3,3-trifluoro-n-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-hydroxypropanamide Chemical compound O=C([C@](O)(C=1C=C(F)C(Cl)=CC=1)C(F)(F)F)NCC1=CC(C(F)(F)F)=CC=C1F HNNCNBYDSNFDDX-OAHLLOKOSA-N 0.000 claims 1
- IEWWEFAALLOHSC-OAHLLOKOSA-N (2r)-3,3,3-trifluoro-2-hydroxy-2-phenyl-n-[(2,3,5-trifluorophenyl)methyl]propanamide Chemical compound O=C([C@](O)(C=1C=CC=CC=1)C(F)(F)F)NCC1=CC(F)=CC(F)=C1F IEWWEFAALLOHSC-OAHLLOKOSA-N 0.000 claims 1
- NSGNSPYQGXAFSN-OAHLLOKOSA-N (2r)-3,3,4,4,4-pentafluoro-n-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hydroxy-2-phenylbutanamide Chemical compound CC1=CN=C(F)C(CNC(=O)[C@](O)(C=2C=CC=CC=2)C(F)(F)C(F)(F)F)=C1 NSGNSPYQGXAFSN-OAHLLOKOSA-N 0.000 claims 1
- RZNKQBAQPJKVOI-OAHLLOKOSA-N (2r)-3,3,4,4,4-pentafluoro-n-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-hydroxy-2-phenylbutanamide Chemical compound O=C([C@](O)(C=1C=CC=CC=1)C(F)(F)C(F)(F)F)NCC1=CC(C(F)(F)F)=CC=C1F RZNKQBAQPJKVOI-OAHLLOKOSA-N 0.000 claims 1
- LJURUBHTNOKMEK-QGZVFWFLSA-N (2r)-n-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hydroxy-2-phenylbutanamide Chemical compound O=C([C@@](O)(CC)C=1C=CC=CC=1)NCC1=CC(C)=CN=C1F LJURUBHTNOKMEK-QGZVFWFLSA-N 0.000 claims 1
- VBKZMLMVKRNZOP-GOSISDBHSA-N (2r)-n-[(4-cyano-5-ethyl-2-fluorophenyl)methyl]-3,3,3-trifluoro-2-hydroxy-2-phenylpropanamide Chemical compound C1=C(C#N)C(CC)=CC(CNC(=O)[C@](O)(C=2C=CC=CC=2)C(F)(F)F)=C1F VBKZMLMVKRNZOP-GOSISDBHSA-N 0.000 claims 1
- UYYWXNVYNNWNPN-OAHLLOKOSA-N (2r)-n-[(5-bromo-2-fluorophenyl)methyl]-3,3,3-trifluoro-2-hydroxy-2-phenylpropanamide Chemical compound O=C([C@](O)(C=1C=CC=CC=1)C(F)(F)F)NCC1=CC(Br)=CC=C1F UYYWXNVYNNWNPN-OAHLLOKOSA-N 0.000 claims 1
- YDLZMUBWZZTBLG-OAHLLOKOSA-N (2r)-n-[(5-chloro-2-fluorophenyl)methyl]-3,3,3-trifluoro-2-hydroxy-2-phenylpropanamide Chemical compound O=C([C@](O)(C=1C=CC=CC=1)C(F)(F)F)NCC1=CC(Cl)=CC=C1F YDLZMUBWZZTBLG-OAHLLOKOSA-N 0.000 claims 1
- UQEYXVNFJCKIET-GOSISDBHSA-N (2r)-n-[(5-cyclopropyl-2-fluorophenyl)methyl]-3,3,4,4,4-pentafluoro-2-hydroxy-2-phenylbutanamide Chemical compound O=C([C@](O)(C=1C=CC=CC=1)C(F)(F)C(F)(F)F)NCC(C(=CC=1)F)=CC=1C1CC1 UQEYXVNFJCKIET-GOSISDBHSA-N 0.000 claims 1
- COLQLWGKRZOYFC-OAHLLOKOSA-N (2r)-n-[(5-cyclopropyl-2-fluoropyridin-3-yl)methyl]-2-(3,4-dichlorophenyl)butanamide Chemical compound O=C([C@H](CC)C=1C=C(Cl)C(Cl)=CC=1)NCC(C(=NC=1)F)=CC=1C1CC1 COLQLWGKRZOYFC-OAHLLOKOSA-N 0.000 claims 1
- ABYCQYBNFPENTN-QGZVFWFLSA-N (2r)-n-[(5-ethyl-2-fluorophenyl)methyl]-3,3,3-trifluoro-2-hydroxy-2-phenylpropanamide Chemical compound CCC1=CC=C(F)C(CNC(=O)[C@](O)(C=2C=CC=CC=2)C(F)(F)F)=C1 ABYCQYBNFPENTN-QGZVFWFLSA-N 0.000 claims 1
- OOWJHBQWBMZGBJ-GOSISDBHSA-N (2r)-n-[(5-ethyl-2-fluoropyridin-3-yl)methyl]-2-hydroxy-2-phenylbutanamide Chemical compound CCC1=CN=C(F)C(CNC(=O)[C@@](O)(CC)C=2C=CC=CC=2)=C1 OOWJHBQWBMZGBJ-GOSISDBHSA-N 0.000 claims 1
- BTUSAGMRJFOYJG-QGZVFWFLSA-N (2r)-n-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-hydroxy-2-phenylbutanamide Chemical compound O=C([C@@](O)(CC)C=1C=CC=CC=1)NCC1=CC(C(F)(F)F)=CC=C1F BTUSAGMRJFOYJG-QGZVFWFLSA-N 0.000 claims 1
- ABSVKUQMEMAYBO-MRXNPFEDSA-N (2r)-n-[[3-cyano-2-fluoro-5-(trifluoromethyl)phenyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-phenylpropanamide Chemical compound O=C([C@](O)(C=1C=CC=CC=1)C(F)(F)F)NCC1=CC(C(F)(F)F)=CC(C#N)=C1F ABSVKUQMEMAYBO-MRXNPFEDSA-N 0.000 claims 1
- XSJFQSRYOWBLNY-KRWDZBQOSA-N (2s)-2-(3-chlorophenyl)-n-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-hydroxybutanamide Chemical compound O=C([C@](O)(CC)C=1C=C(Cl)C=CC=1)NCC1=CC(C(F)(F)F)=CC=C1F XSJFQSRYOWBLNY-KRWDZBQOSA-N 0.000 claims 1
- HNNCNBYDSNFDDX-HNNXBMFYSA-N (2s)-2-(4-chloro-3-fluorophenyl)-3,3,3-trifluoro-n-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-hydroxypropanamide Chemical compound O=C([C@@](O)(C=1C=C(F)C(Cl)=CC=1)C(F)(F)F)NCC1=CC(C(F)(F)F)=CC=C1F HNNCNBYDSNFDDX-HNNXBMFYSA-N 0.000 claims 1
- SEXSZNASUHPUPT-HNNXBMFYSA-N (2s)-3,3,3-trifluoro-n-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hydroxy-2-phenylpropanamide Chemical compound CC1=CN=C(F)C(CNC(=O)[C@@](O)(C=2C=CC=CC=2)C(F)(F)F)=C1 SEXSZNASUHPUPT-HNNXBMFYSA-N 0.000 claims 1
- NSGNSPYQGXAFSN-HNNXBMFYSA-N (2s)-3,3,4,4,4-pentafluoro-n-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hydroxy-2-phenylbutanamide Chemical compound CC1=CN=C(F)C(CNC(=O)[C@@](O)(C=2C=CC=CC=2)C(F)(F)C(F)(F)F)=C1 NSGNSPYQGXAFSN-HNNXBMFYSA-N 0.000 claims 1
- RZNKQBAQPJKVOI-HNNXBMFYSA-N (2s)-3,3,4,4,4-pentafluoro-n-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-hydroxy-2-phenylbutanamide Chemical compound O=C([C@@](O)(C=1C=CC=CC=1)C(F)(F)C(F)(F)F)NCC1=CC(C(F)(F)F)=CC=C1F RZNKQBAQPJKVOI-HNNXBMFYSA-N 0.000 claims 1
- ROROYOIYWUWEAJ-HNNXBMFYSA-N (2s)-n-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-phenylbutanamide Chemical compound O=C([C@@H](CC)C=1C=CC=CC=1)NCC1=CC(C)=CN=C1F ROROYOIYWUWEAJ-HNNXBMFYSA-N 0.000 claims 1
- VLNKNIFVOBPSMC-HNNXBMFYSA-N (2s)-n-[(5-bromo-2-fluorophenyl)methyl]-2-phenylbutanamide Chemical compound O=C([C@@H](CC)C=1C=CC=CC=1)NCC1=CC(Br)=CC=C1F VLNKNIFVOBPSMC-HNNXBMFYSA-N 0.000 claims 1
- UQEYXVNFJCKIET-SFHVURJKSA-N (2s)-n-[(5-cyclopropyl-2-fluorophenyl)methyl]-3,3,4,4,4-pentafluoro-2-hydroxy-2-phenylbutanamide Chemical compound O=C([C@@](O)(C=1C=CC=CC=1)C(F)(F)C(F)(F)F)NCC(C(=CC=1)F)=CC=1C1CC1 UQEYXVNFJCKIET-SFHVURJKSA-N 0.000 claims 1
- COLQLWGKRZOYFC-HNNXBMFYSA-N (2s)-n-[(5-cyclopropyl-2-fluoropyridin-3-yl)methyl]-2-(3,4-dichlorophenyl)butanamide Chemical compound O=C([C@@H](CC)C=1C=C(Cl)C(Cl)=CC=1)NCC(C(=NC=1)F)=CC=1C1CC1 COLQLWGKRZOYFC-HNNXBMFYSA-N 0.000 claims 1
- HXIAUKFEZJLDIT-KRWDZBQOSA-N (2s)-n-[(5-cyclopropyl-2-fluoropyridin-3-yl)methyl]-2-phenylbutanamide Chemical compound O=C([C@@H](CC)C=1C=CC=CC=1)NCC(C(=NC=1)F)=CC=1C1CC1 HXIAUKFEZJLDIT-KRWDZBQOSA-N 0.000 claims 1
- PXZKOPPVRIJGGB-KRWDZBQOSA-N (2s)-n-[(5-ethyl-2-fluorophenyl)methyl]-2-phenylbutanamide Chemical compound O=C([C@@H](CC)C=1C=CC=CC=1)NCC1=CC(CC)=CC=C1F PXZKOPPVRIJGGB-KRWDZBQOSA-N 0.000 claims 1
- OOWJHBQWBMZGBJ-SFHVURJKSA-N (2s)-n-[(5-ethyl-2-fluoropyridin-3-yl)methyl]-2-hydroxy-2-phenylbutanamide Chemical compound CCC1=CN=C(F)C(CNC(=O)[C@](O)(CC)C=2C=CC=CC=2)=C1 OOWJHBQWBMZGBJ-SFHVURJKSA-N 0.000 claims 1
- DTLORZJLDDAITP-INIZCTEOSA-N (2s)-n-[(5-ethyl-2-fluoropyridin-3-yl)methyl]-2-phenylbutanamide Chemical compound O=C([C@@H](CC)C=1C=CC=CC=1)NCC1=CC(CC)=CN=C1F DTLORZJLDDAITP-INIZCTEOSA-N 0.000 claims 1
- BTUSAGMRJFOYJG-KRWDZBQOSA-N (2s)-n-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-hydroxy-2-phenylbutanamide Chemical compound O=C([C@](O)(CC)C=1C=CC=CC=1)NCC1=CC(C(F)(F)F)=CC=C1F BTUSAGMRJFOYJG-KRWDZBQOSA-N 0.000 claims 1
- JOJCMUGQTZHAFQ-HNNXBMFYSA-N (2s)-n-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-phenylbutanamide Chemical compound O=C([C@@H](CC)C=1C=CC=CC=1)NCC1=CC(C(F)(F)F)=CC=C1F JOJCMUGQTZHAFQ-HNNXBMFYSA-N 0.000 claims 1
- FUTXZOUYRWNGAO-AWEZNQCLSA-N (2s)-n-[[2-fluoro-5-(trifluoromethyl)pyridin-3-yl]methyl]-2-phenylbutanamide Chemical compound O=C([C@@H](CC)C=1C=CC=CC=1)NCC1=CC(C(F)(F)F)=CN=C1F FUTXZOUYRWNGAO-AWEZNQCLSA-N 0.000 claims 1
- USHFGOGPBYRMNY-HNNXBMFYSA-N (2s)-n-[[3-bromo-2-fluoro-5-(trifluoromethyl)phenyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-phenylpropanamide Chemical compound O=C([C@@](O)(C=1C=CC=CC=1)C(F)(F)F)NCC1=CC(C(F)(F)F)=CC(Br)=C1F USHFGOGPBYRMNY-HNNXBMFYSA-N 0.000 claims 1
- SEXSZNASUHPUPT-UHFFFAOYSA-N 3,3,3-trifluoro-n-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-hydroxy-2-phenylpropanamide Chemical compound CC1=CN=C(F)C(CNC(=O)C(O)(C=2C=CC=CC=2)C(F)(F)F)=C1 SEXSZNASUHPUPT-UHFFFAOYSA-N 0.000 claims 1
- 229940121819 ATPase inhibitor Drugs 0.000 claims 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 102100033367 Appetite-regulating hormone Human genes 0.000 claims 1
- 101710111255 Appetite-regulating hormone Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 102000055006 Calcitonin Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- 229940123613 Calcium receptor antagonist Drugs 0.000 claims 1
- 229940122156 Cathepsin K inhibitor Drugs 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 208000036119 Frailty Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 102000002265 Human Growth Hormone Human genes 0.000 claims 1
- 108010000521 Human Growth Hormone Proteins 0.000 claims 1
- 239000000854 Human Growth Hormone Substances 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 claims 1
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010027304 Menopausal symptoms Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 102000008108 Osteoprotegerin Human genes 0.000 claims 1
- 108010035042 Osteoprotegerin Proteins 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 102000013275 Somatomedins Human genes 0.000 claims 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims 1
- 102000011731 Vacuolar Proton-Translocating ATPases Human genes 0.000 claims 1
- 108010037026 Vacuolar Proton-Translocating ATPases Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 229930003448 Vitamin K Natural products 0.000 claims 1
- LXCFTLNNPFEIHC-INIZCTEOSA-N [(2r)-3-[(2-fluoro-5-methylpyridin-3-yl)methylamino]-3-oxo-2-phenylpropyl] n,n-dimethylcarbamate Chemical compound O=C([C@@H](COC(=O)N(C)C)C=1C=CC=CC=1)NCC1=CC(C)=CN=C1F LXCFTLNNPFEIHC-INIZCTEOSA-N 0.000 claims 1
- CDGGBWJOZAQXAV-SFHVURJKSA-N [(2r)-3-[(2-fluoro-5-methylpyridin-3-yl)methylamino]-3-oxo-2-phenylpropyl] pyrrolidine-1-carboxylate Chemical compound CC1=CN=C(F)C(CNC(=O)[C@@H](COC(=O)N2CCCC2)C=2C=CC=CC=2)=C1 CDGGBWJOZAQXAV-SFHVURJKSA-N 0.000 claims 1
- GJOGLIRTUXJPBH-INIZCTEOSA-N [(2r)-3-[[2-fluoro-5-(trifluoromethyl)phenyl]methylamino]-3-oxo-2-phenylpropyl] n,n-dimethylcarbamate Chemical compound O=C([C@@H](COC(=O)N(C)C)C=1C=CC=CC=1)NCC1=CC(C(F)(F)F)=CC=C1F GJOGLIRTUXJPBH-INIZCTEOSA-N 0.000 claims 1
- KSSALMVCYLZVPI-SFHVURJKSA-N [(2r)-3-[[2-fluoro-5-(trifluoromethyl)phenyl]methylamino]-3-oxo-2-phenylpropyl] pyrrolidine-1-carboxylate Chemical compound FC1=CC=C(C(F)(F)F)C=C1CNC(=O)[C@H](C=1C=CC=CC=1)COC(=O)N1CCCC1 KSSALMVCYLZVPI-SFHVURJKSA-N 0.000 claims 1
- LXCFTLNNPFEIHC-MRXNPFEDSA-N [(2s)-3-[(2-fluoro-5-methylpyridin-3-yl)methylamino]-3-oxo-2-phenylpropyl] n,n-dimethylcarbamate Chemical compound O=C([C@H](COC(=O)N(C)C)C=1C=CC=CC=1)NCC1=CC(C)=CN=C1F LXCFTLNNPFEIHC-MRXNPFEDSA-N 0.000 claims 1
- CDGGBWJOZAQXAV-GOSISDBHSA-N [(2s)-3-[(2-fluoro-5-methylpyridin-3-yl)methylamino]-3-oxo-2-phenylpropyl] pyrrolidine-1-carboxylate Chemical compound CC1=CN=C(F)C(CNC(=O)[C@H](COC(=O)N2CCCC2)C=2C=CC=CC=2)=C1 CDGGBWJOZAQXAV-GOSISDBHSA-N 0.000 claims 1
- GJOGLIRTUXJPBH-MRXNPFEDSA-N [(2s)-3-[[2-fluoro-5-(trifluoromethyl)phenyl]methylamino]-3-oxo-2-phenylpropyl] n,n-dimethylcarbamate Chemical compound O=C([C@H](COC(=O)N(C)C)C=1C=CC=CC=1)NCC1=CC(C(F)(F)F)=CC=C1F GJOGLIRTUXJPBH-MRXNPFEDSA-N 0.000 claims 1
- KSSALMVCYLZVPI-GOSISDBHSA-N [(2s)-3-[[2-fluoro-5-(trifluoromethyl)phenyl]methylamino]-3-oxo-2-phenylpropyl] pyrrolidine-1-carboxylate Chemical compound FC1=CC=C(C(F)(F)F)C=C1CNC(=O)[C@@H](C=1C=CC=CC=1)COC(=O)N1CCCC1 KSSALMVCYLZVPI-GOSISDBHSA-N 0.000 claims 1
- 230000003187 abdominal effect Effects 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 229940062527 alendronate Drugs 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 1
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 claims 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 206010003549 asthenia Diseases 0.000 claims 1
- 229940112869 bone morphogenetic protein Drugs 0.000 claims 1
- 229960004015 calcitonin Drugs 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 229940069978 calcium supplement Drugs 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 230000000378 dietary effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- 201000003585 eunuchism Diseases 0.000 claims 1
- 150000004673 fluoride salts Chemical class 0.000 claims 1
- 201000003617 glucocorticoid-induced osteoporosis Diseases 0.000 claims 1
- 239000003324 growth hormone secretagogue Substances 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229960005431 ipriflavone Drugs 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 208000037106 male hypogonadism Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- HXCCXUWPISVJRA-UHFFFAOYSA-N n-[(2-fluoro-5-methylphenyl)methyl]-2-phenylbutanamide Chemical compound C=1C=CC=CC=1C(CC)C(=O)NCC1=CC(C)=CC=C1F HXCCXUWPISVJRA-UHFFFAOYSA-N 0.000 claims 1
- ROROYOIYWUWEAJ-UHFFFAOYSA-N n-[(2-fluoro-5-methylpyridin-3-yl)methyl]-2-phenylbutanamide Chemical compound C=1C=CC=CC=1C(CC)C(=O)NCC1=CC(C)=CN=C1F ROROYOIYWUWEAJ-UHFFFAOYSA-N 0.000 claims 1
- VLNKNIFVOBPSMC-UHFFFAOYSA-N n-[(5-bromo-2-fluorophenyl)methyl]-2-phenylbutanamide Chemical compound C=1C=CC=CC=1C(CC)C(=O)NCC1=CC(Br)=CC=C1F VLNKNIFVOBPSMC-UHFFFAOYSA-N 0.000 claims 1
- YLBXEYCFAGJNOW-UHFFFAOYSA-N n-[(5-cyclopropyl-2-fluorophenyl)methyl]-2-phenylbutanamide Chemical compound C=1C=CC=CC=1C(CC)C(=O)NCC(C(=CC=1)F)=CC=1C1CC1 YLBXEYCFAGJNOW-UHFFFAOYSA-N 0.000 claims 1
- UAJUEDTYIVUMKP-UHFFFAOYSA-N n-[(5-cyclopropyl-2-fluorophenyl)methyl]-3,3,3-trifluoro-2-(4-fluorophenyl)-2-hydroxypropanamide Chemical compound C=1C=C(F)C=CC=1C(C(F)(F)F)(O)C(=O)NCC(C(=CC=1)F)=CC=1C1CC1 UAJUEDTYIVUMKP-UHFFFAOYSA-N 0.000 claims 1
- ISKVQYWSYZQLPU-UHFFFAOYSA-N n-[(5-ethenyl-2-fluorophenyl)methyl]-2-phenylbutanamide Chemical compound C=1C=CC=CC=1C(CC)C(=O)NCC1=CC(C=C)=CC=C1F ISKVQYWSYZQLPU-UHFFFAOYSA-N 0.000 claims 1
- PXZKOPPVRIJGGB-UHFFFAOYSA-N n-[(5-ethyl-2-fluorophenyl)methyl]-2-phenylbutanamide Chemical compound C=1C=CC=CC=1C(CC)C(=O)NCC1=CC(CC)=CC=C1F PXZKOPPVRIJGGB-UHFFFAOYSA-N 0.000 claims 1
- JOJCMUGQTZHAFQ-UHFFFAOYSA-N n-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-phenylbutanamide Chemical compound C=1C=CC=CC=1C(CC)C(=O)NCC1=CC(C(F)(F)F)=CC=C1F JOJCMUGQTZHAFQ-UHFFFAOYSA-N 0.000 claims 1
- USHFGOGPBYRMNY-UHFFFAOYSA-N n-[[3-bromo-2-fluoro-5-(trifluoromethyl)phenyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-phenylpropanamide Chemical compound C=1C=CC=CC=1C(C(F)(F)F)(O)C(=O)NCC1=CC(C(F)(F)F)=CC(Br)=C1F USHFGOGPBYRMNY-UHFFFAOYSA-N 0.000 claims 1
- GLWLJRFLFJLVGZ-UHFFFAOYSA-N n-[[5-(1,1-difluoroethyl)-2-fluorophenyl]methyl]-2-phenylbutanamide Chemical compound C=1C=CC=CC=1C(CC)C(=O)NCC1=CC(C(C)(F)F)=CC=C1F GLWLJRFLFJLVGZ-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims 1
- 206010036601 premature menopause Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000583 progesterone congener Substances 0.000 claims 1
- 239000003909 protein kinase inhibitor Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000002278 reconstructive surgery Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000005495 thyroid hormone Substances 0.000 claims 1
- 229940036555 thyroid hormone Drugs 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 235000019168 vitamin K Nutrition 0.000 claims 1
- 239000011712 vitamin K Substances 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- 229940046010 vitamin k Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57769804P | 2004-06-07 | 2004-06-07 | |
| US60/577,698 | 2004-06-07 | ||
| PCT/US2005/019554 WO2005120477A2 (en) | 2004-06-07 | 2005-06-03 | N- (2-benzyl) -2-phenylbutanamides as androgen receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008501800A JP2008501800A (ja) | 2008-01-24 |
| JP2008501800A5 true JP2008501800A5 (https=) | 2008-04-10 |
| JP4881865B2 JP4881865B2 (ja) | 2012-02-22 |
Family
ID=35415107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527597A Expired - Fee Related JP4881865B2 (ja) | 2004-06-07 | 2005-06-03 | アンドロゲン受容体調節剤としてのｎ−（２−ベンジル）−２−フェニルブタンアミド |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US7268153B2 (https=) |
| EP (1) | EP1755572B1 (https=) |
| JP (1) | JP4881865B2 (https=) |
| CN (1) | CN1976902A (https=) |
| AR (1) | AR049140A1 (https=) |
| AT (1) | ATE545631T1 (https=) |
| AU (1) | AU2005251766B9 (https=) |
| BR (1) | BRPI0511862A (https=) |
| CA (1) | CA2569124C (https=) |
| CR (1) | CR8777A (https=) |
| EC (1) | ECSP067061A (https=) |
| IL (1) | IL179843A0 (https=) |
| MA (1) | MA28677B1 (https=) |
| MX (1) | MXPA06014235A (https=) |
| MY (1) | MY147997A (https=) |
| NO (1) | NO20070085L (https=) |
| NZ (1) | NZ551738A (https=) |
| PE (1) | PE20060401A1 (https=) |
| RU (1) | RU2378255C2 (https=) |
| SG (1) | SG169398A1 (https=) |
| TW (1) | TW200610755A (https=) |
| UA (1) | UA87854C2 (https=) |
| WO (1) | WO2005120477A2 (https=) |
| ZA (1) | ZA200609673B (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| JP2008518968A (ja) * | 2004-10-29 | 2008-06-05 | メルク エンド カムパニー インコーポレーテッド | アンドロゲン受容体モジュレーターとしてのｎ−（ピリジン−３−イル）−２−フェニルブタンアミド |
| AU2006275699A1 (en) * | 2005-08-02 | 2007-02-08 | Merck Sharp & Dohme Corp. | N-(pyridin-4-yl)-2-phenylbutanamides as androgen receptor modulators |
| JP2009522246A (ja) * | 2005-12-30 | 2009-06-11 | ランバクシー ラボラトリーズ リミテッド | ムスカリン性レセプターアンタゴニスト |
| AU2007313295A1 (en) * | 2006-10-18 | 2008-04-24 | Merck Sharp & Dohme Corp. | 2-hydroxy-2-phenyl/thiophenyl propionamides as androgen receptor modulators |
| KR101595238B1 (ko) | 2007-12-21 | 2016-02-18 | 리간드 파마슈티칼스 인코포레이티드 | 선택적 안드로겐 수용체 조절제(ｓａｒｍ) 및 이의 용도 |
| US20090197947A1 (en) * | 2008-02-01 | 2009-08-06 | The Research Foundation Of State University Of New York | Medicaments and methods for lowering plasma lipid levels and screening drugs |
| US8623909B2 (en) * | 2008-05-09 | 2014-01-07 | Aska Pharmaceutical Co., Ltd. | Prophylactic/therapeutic agents for lifestyle-related diseases |
| HUE033581T2 (hu) | 2010-06-10 | 2017-12-28 | Seragon Pharmaceuticals Inc | Ösztrogén receptor modulátorok és alkalmazásaik |
| US9282979B2 (en) | 2010-06-24 | 2016-03-15 | DePuy Synthes Products, Inc. | Instruments and methods for non-parallel disc space preparation |
| FR2982261B1 (fr) * | 2011-11-04 | 2014-06-13 | Galderma Res & Dev | Nouveaux amides, et leur utilisation pharmaceutique ou cosmetique |
| JP6112625B2 (ja) | 2011-12-14 | 2017-04-12 | セラゴン ファーマシューティカルズ，インク． | フッ素化したエストロゲン受容体モジュレーターおよびその使用 |
| CN103288669B (zh) * | 2013-07-01 | 2015-06-24 | 南开大学 | 一种阿卓乳酸酰胺衍生物及应用 |
| US9868705B2 (en) | 2013-09-27 | 2018-01-16 | The Board Of Trustees Of The University Of Illinois | Tetra-aryl cyclobutane inhibitors of androgen receptor action for the treatment of hormone refractory cancer |
| EP3094323A4 (en) | 2014-01-17 | 2017-10-11 | Ligand Pharmaceuticals Incorporated | Methods and compositions for modulating hormone levels |
| US10806720B2 (en) | 2015-04-21 | 2020-10-20 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| CA2983426C (en) * | 2015-04-21 | 2023-10-17 | Gtx, Inc. | Selective androgen receptor degrader (sard) ligands and methods of use thereof |
| US10654809B2 (en) | 2016-06-10 | 2020-05-19 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10865184B2 (en) | 2015-04-21 | 2020-12-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10441570B2 (en) | 2015-04-21 | 2019-10-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) Ligands and methods of use thereof |
| US10093613B2 (en) | 2015-04-21 | 2018-10-09 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US11230523B2 (en) | 2016-06-10 | 2022-01-25 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| WO2019071147A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| WO2019222272A1 (en) | 2018-05-14 | 2019-11-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
| WO2020051344A1 (en) | 2018-09-05 | 2020-03-12 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (sard) ligands and methods of use thereof |
| AU2020257397B2 (en) | 2019-04-19 | 2026-02-26 | Ligand Pharmaceuticals Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| CN113811333B (zh) | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | 靶向抗癌核激素受体的化合物 |
| US20210024636A1 (en) * | 2019-07-26 | 2021-01-28 | Chemistryrx | Compositions and methods for treating sexual dysfunction |
| WO2021097046A1 (en) | 2019-11-13 | 2021-05-20 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| KR20230160299A (ko) | 2021-03-23 | 2023-11-23 | 누베이션 바이오 인크. | 항암 핵 호르몬 수용체 표적화 화합물 |
| US12006314B2 (en) | 2021-05-03 | 2024-06-11 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CN113816900B (zh) * | 2021-10-18 | 2024-06-25 | 宁夏瑞泰科技股份有限公司 | 一种2-氯-5-甲基吡啶-3-甲醛的合成方法 |
Family Cites Families (139)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2809965A (en) | 1956-04-30 | 1957-10-15 | Dow Chemical Co | Phthalides |
| CA777769A (en) | 1963-03-18 | 1968-02-06 | H. Roy Clarence | Substituted methylene diphosphonic acid compounds and detergent compositions |
| US3239345A (en) | 1965-02-15 | 1966-03-08 | Estrogenic compounds and animal growth promoters | |
| US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| US4036979A (en) | 1974-01-25 | 1977-07-19 | American Cyanamid Company | Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate |
| US4342767A (en) | 1980-01-23 | 1982-08-03 | Merck & Co., Inc. | Hypocholesteremic fermentation products |
| US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
| FR2531088B1 (fr) | 1982-07-29 | 1987-08-28 | Sanofi Sa | Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation |
| US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| GB8332704D0 (en) | 1983-12-07 | 1984-01-11 | Pfizer Ltd | Growth promotants for animals |
| US4761406A (en) | 1985-06-06 | 1988-08-02 | The Procter & Gamble Company | Regimen for treating osteoporosis |
| DE3623397A1 (de) | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| GB8726179D0 (en) * | 1987-11-09 | 1987-12-16 | Fujisawa Pharmaceutical Co | Heterocyclic derivatives |
| CA1339805C (en) | 1988-01-20 | 1998-04-07 | Yasuo Isomura | (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active |
| US4922007A (en) | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5019651A (en) | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
| US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
| US5206235A (en) | 1991-03-20 | 1993-04-27 | Merck & Co., Inc. | Benzo-fused lactams that promote the release of growth hormone |
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| US5283241A (en) | 1992-08-28 | 1994-02-01 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
| US5583130A (en) | 1992-09-25 | 1996-12-10 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
| US5317017A (en) | 1992-09-30 | 1994-05-31 | Merck & Co., Inc. | N-biphenyl-3-amido substituted benzolactams stimulate growth hormone release |
| US5374721A (en) | 1992-10-14 | 1994-12-20 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
| EP0669830A4 (en) | 1992-11-06 | 1997-02-26 | Merck & Co Inc | SUBSTITUTED DIPEPTIDE ANALOGS, WHICH SUPPORT THE RELEASE OF GROWTH HORMONE. |
| NZ258412A (en) | 1992-12-11 | 1997-01-29 | Merck & Co Inc | Spiro-fused piperidine derivatives and pharmaceutical compositions |
| US5536716A (en) | 1992-12-11 | 1996-07-16 | Merck & Co., Inc. | Spiro piperidines and homologs which promote release of growth hormone |
| US5284841A (en) | 1993-02-04 | 1994-02-08 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
| US5434261A (en) | 1993-07-26 | 1995-07-18 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
| US5430144A (en) | 1993-07-26 | 1995-07-04 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
| US5952281A (en) | 1993-08-04 | 1999-09-14 | Colgate Palmolive Company | Aqueous cleaning composition which may be in microemulsion form containing a silicone antifoam agent |
| TW257765B (https=) | 1993-08-25 | 1995-09-21 | Merck & Co Inc | |
| US5510517A (en) | 1993-08-25 | 1996-04-23 | Merck & Co., Inc. | Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids |
| US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| DE4332384A1 (de) | 1993-09-23 | 1995-03-30 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten III |
| US5545735A (en) | 1993-10-04 | 1996-08-13 | Merck & Co., Inc. | Benzo-Fused Lactams promote release of growth hormone |
| HUT75224A (en) | 1993-10-19 | 1997-04-28 | Merck & Co Inc | Combination of bisphosphonates and growth hormone secretagogues |
| US5438136A (en) | 1993-11-02 | 1995-08-01 | Merck & Co., Inc. | Benzo-fused macrocycles promote release of growth hormone |
| US5492916A (en) | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| US5494919A (en) | 1993-11-09 | 1996-02-27 | Merck & Co., Inc. | 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| PL322706A1 (en) | 1993-11-09 | 1998-02-16 | Merck & Co Inc | Piperidines, pyrolidines and hexahydro-1h-azepins enhancing growth hormone liberation |
| CA2176140A1 (en) | 1993-11-24 | 1995-06-01 | Meng Hsin Chen | Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s) |
| WO1995016675A1 (en) | 1993-12-13 | 1995-06-22 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
| US5606054A (en) | 1993-12-14 | 1997-02-25 | Merck & Co., Inc. | Heterocyclic-fused lactams promote release of growth hormone |
| JP3759748B2 (ja) | 1993-12-23 | 2006-03-29 | ノボ ノルディスク アクティーゼルスカブ | 成長ホルモン放出性を有する化合物 |
| HU224345B1 (hu) | 1993-12-23 | 2005-08-29 | Novo Nordisk A/S. | Növekedési hormont felszabadító tulajdonságú peptidek, ezeket hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk |
| US5501969A (en) | 1994-03-08 | 1996-03-26 | Human Genome Sciences, Inc. | Human osteoclast-derived cathepsin |
| JPH10501222A (ja) | 1994-05-27 | 1998-02-03 | メルク エンド カンパニー インコーポレーテッド | 破骨細胞仲介骨吸収を抑制するための化合物 |
| WO1995034311A1 (en) | 1994-06-13 | 1995-12-21 | Merck & Co., Inc. | Piperazine compounds promote release of growth hormone |
| EP0762882A4 (en) | 1994-06-29 | 2002-09-11 | Smithkline Beecham Corp | Vibronectin Receptor Antagonists |
| EP0767792A4 (en) | 1994-06-29 | 2002-11-20 | Smithkline Beecham Corp | VITRONECTIN RECEPTOR ANTAGONISTS |
| US5783582A (en) | 1994-07-20 | 1998-07-21 | Merck & Co., Inc. | Piperidines and hexahydro-1H-azepines spiro substituted at the 4-position promote release of growth hormone |
| US5494920A (en) | 1994-08-22 | 1996-02-27 | Eli Lilly And Company | Methods of inhibiting viral replication |
| JPH10504825A (ja) | 1994-08-22 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | 二環式化合物 |
| US5736357A (en) | 1994-10-27 | 1998-04-07 | Arris Pharmaceutical | Cathespin O protease |
| US6544767B1 (en) | 1994-10-27 | 2003-04-08 | Axys Pharmaceuticals, Inc. | Cathespin O2 protease |
| DE19504379A1 (de) | 1995-02-10 | 1996-08-14 | Hoechst Ag | Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate sowie sie enthaltende pharmazeutische Präparate |
| WO1996026190A1 (en) | 1995-02-22 | 1996-08-29 | Smithkline Beecham Corporation | Integrin receptor antagonists |
| US5710159A (en) | 1996-05-09 | 1998-01-20 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| PT910563E (pt) | 1995-06-29 | 2003-09-30 | Smithkline Beecham Corp | Antagonistas de receptores de integrina |
| US6008213A (en) | 1995-06-29 | 1999-12-28 | Smithkline Beecham Corporation | Integrin receptor antagonists |
| BR9610422A (pt) | 1995-08-30 | 1999-07-13 | Searle & Co | Derivados de meta-guanidina uréia tiouréia ou ácido aminobenzóico azacíclico como antagonistas de integrina |
| US6204293B1 (en) * | 1995-11-06 | 2001-03-20 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| WO1997023200A1 (en) | 1995-12-22 | 1997-07-03 | Kowa Company, Ltd. | Pharmaceutical composition stabilized with a basic agent |
| JP2000502704A (ja) | 1995-12-29 | 2000-03-07 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗物質 |
| PL327694A1 (en) | 1995-12-29 | 1998-12-21 | Smithkline Beecham Corp | Antagonists of vitronectin receptor |
| EP0895475A4 (en) | 1995-12-29 | 2000-08-23 | Smithkline Beecham Corp | VITRONECTIN RECEPTOR ANTAGONISTS |
| EP0796855B1 (de) | 1996-03-20 | 2002-02-06 | Hoechst Aktiengesellschaft | Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| SI9720021A (sl) | 1996-03-20 | 1999-04-30 | Hoechst Marion Roussel | Triciklične spojine s specifično aktivnostjo za integrine, zlasti za integrine alfavbeta3, postopki za njihovo pripravo in intermediati teh postopkov, njihova aplikacija kot zdravila in farmacevtski sestavki, ki jih vsebujejo |
| AU2323897A (en) | 1996-03-29 | 1997-10-22 | G.D. Searle & Co. | Cyclopropyl alkanoic acid derivatives |
| PT889876E (pt) | 1996-03-29 | 2001-11-30 | Searle & Co | Derivados de fenilenossulfonamidas meta-substituidas |
| DE69713582T2 (de) | 1996-03-29 | 2003-01-09 | G.D. Searle & Co., Chicago | Zimtsäurederivate und deren verwendung als integrin-antagonisten |
| PT889877E (pt) | 1996-03-29 | 2002-02-28 | Searle & Co | Derivados fenileno meta substituidos e sua utilizacao como antagonitas ou inibidores integrina alfa v beta3 |
| US5925655A (en) | 1996-04-10 | 1999-07-20 | Merck & Co., Inc. | αv β3 antagonists |
| KR20000022190A (ko) | 1996-06-28 | 2000-04-25 | 플레믹 크리스티안 | 인테그린 저해제로서의 페닐알라닌 유도체 |
| DE19629817A1 (de) | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| DE19629816A1 (de) | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| US5981546A (en) | 1996-08-29 | 1999-11-09 | Merck & Co., Inc. | Integrin antagonists |
| UA60311C2 (uk) | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція |
| JP2001501951A (ja) | 1996-10-07 | 2001-02-13 | スミスクライン・ビーチャム・コーポレイション | 骨形成刺激方法 |
| US5919792A (en) | 1996-10-30 | 1999-07-06 | Merck & Co., Inc. | Integrin antagonists |
| WO1998023608A1 (en) | 1996-11-27 | 1998-06-04 | Dupont Pharmaceuticals Company | Novel integrin receptor antagonists |
| DE19653646A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung |
| CO4920232A1 (es) | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin |
| DE19705450A1 (de) | 1997-02-13 | 1998-08-20 | Merck Patent Gmbh | Bicyclische aromatische Aminosäuren |
| JP2002510328A (ja) | 1997-07-25 | 2002-04-02 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体アンタゴニスト |
| JP2001511452A (ja) | 1997-08-04 | 2001-08-14 | スミスクライン・ビーチャム・コーポレイション | インテグリン受容体アンタゴニスト |
| CA2304117A1 (en) | 1997-09-04 | 1999-03-11 | Dirk A. Heerding | Integrin receptor antagonists |
| DZ2609A1 (fr) | 1997-09-19 | 2003-03-01 | Smithkline Beecham Corp | Composés nouveaux antagonistes des récepteurs de vitronectine et compositions pharmaceutiques les contenant. |
| CN1273529A (zh) | 1997-09-24 | 2000-11-15 | 史密丝克莱恩比彻姆公司 | 玻连蛋白受体拮抗剂 |
| TR200000786T2 (tr) | 1997-09-24 | 2000-08-21 | Smithkline Beecham Corporation | Vitronektin reseptör antagonisti |
| FR2768736B1 (fr) | 1997-09-24 | 2000-05-26 | Roussel Uclaf | Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
| EP1049693A1 (en) | 1997-11-26 | 2000-11-08 | Du Pont Pharmaceuticals Company | 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS $g(a) v?$g(b) 3? ANTAGONISTS |
| US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| TR200001752T2 (tr) | 1997-12-17 | 2000-12-21 | Merck & Co., Inc. | Entegrin reseptör antagonistleri |
| WO1999030709A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| CA2315232A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6066648A (en) | 1997-12-17 | 2000-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
| EP0933367A1 (en) | 1997-12-19 | 1999-08-04 | Hoechst Marion Roussel Deutschland GmbH | Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists |
| WO1999033798A1 (en) | 1997-12-25 | 1999-07-08 | Yamanouchi Pharmaceutical Co., Ltd. | Nitrogenous heterocyclic derivatives |
| EP0928793B1 (en) | 1998-01-02 | 2002-05-15 | F. Hoffmann-La Roche Ag | Thiazole derivatives |
| EP0928790B1 (en) | 1998-01-02 | 2003-03-05 | F. Hoffmann-La Roche Ag | Thiazole derivatives |
| IL137423A0 (en) | 1998-01-23 | 2001-07-24 | Aventis Pharma Gmbh | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion |
| ZA994406B (en) | 1998-03-04 | 2000-02-11 | Searle & Co | Meta-azacyclic amino benzoic acid and derivatives thereof. |
| KR20010041812A (ko) | 1998-03-10 | 2001-05-25 | 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 | 비트로넥틴 수용체 길항제 |
| ATE542797T1 (de) | 1998-04-09 | 2012-02-15 | Meiji Seika Pharma Co Ltd | Aminopiperidinderivate als integrin alpha v beta 3 antagonisten |
| CZ20003672A3 (cs) | 1998-04-10 | 2001-08-15 | G. D. Searle & Co. | Heterocyklické glycyl-beta-alaninové deriváty jako agonisté vitronektinu |
| WO1999052879A1 (en) | 1998-04-14 | 1999-10-21 | American Home Products Corporation | Acylresorcinol derivatives as selective vitronectin receptor inhibitors |
| EP0960882A1 (en) | 1998-05-19 | 1999-12-01 | Hoechst Marion Roussel Deutschland GmbH | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists |
| AU4385399A (en) | 1998-06-29 | 2000-01-17 | Biochem Pharma Inc. | Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer |
| AR019190A1 (es) | 1998-07-08 | 2001-12-26 | Sod Conseils Rech Applic | Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos |
| AU747784B2 (en) | 1998-07-29 | 2002-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
| WO2000009503A1 (en) | 1998-08-13 | 2000-02-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| GB9828442D0 (en) * | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
| CN1209016C (zh) | 1999-08-18 | 2005-07-06 | 阿方蒂农科有限公司 | 杀真菌剂 |
| WO2001017562A1 (fr) | 1999-09-02 | 2001-03-15 | Yamanouchi Pharmaceutical Co., Ltd. | Agents promoteurs de l'osteogenese |
| WO2001049288A1 (en) | 2000-01-06 | 2001-07-12 | Merck Frosst Canada & Co. | Novel compounds and compositions as protease inhibitors |
| WO2001077073A1 (en) | 2000-04-06 | 2001-10-18 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
| ATE481385T1 (de) | 2000-05-31 | 2010-10-15 | Santen Pharmaceutical Co Ltd | (pyridinyl)alkyl-amide oder -harnstoffe als tnf- alpha bildung inhibitoren |
| EP1193248A1 (en) | 2000-09-30 | 2002-04-03 | Aventis Pharma Deutschland GmbH | Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation and their use |
| US7214690B2 (en) * | 2001-02-23 | 2007-05-08 | Ligand Pharmaceuticals Incorporated | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods |
| JPWO2003030937A1 (ja) * | 2001-10-05 | 2005-01-20 | 小野薬品工業株式会社 | ミトコンドリアルベンゾジアゼピン受容体アンタゴニストからなるストレス疾患の治療剤 |
| PT1480634E (pt) * | 2002-02-07 | 2011-10-12 | Univ Tennessee Res Foundation | Moduladores selectivos do receptor do androgénio (sarms) para o tratamento da hiperplasia benigna da próstata |
| MXPA04008412A (es) * | 2002-02-28 | 2005-05-17 | Univ Tennessee Res Corp | Moduladores irreversibles del receptor de androgeno selectivo y metodos para utilizar los mismos. |
| CA2484173A1 (en) * | 2002-04-30 | 2003-11-13 | Merck & Co., Inc. | 4-azasteroid derivatives as androgen receptor modulators |
| JP2006518328A (ja) * | 2002-10-15 | 2006-08-10 | ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション | 複素環選択的アンドロゲン受容体調節剤及びその使用方法 |
| US20040087810A1 (en) * | 2002-10-23 | 2004-05-06 | Dalton James T. | Irreversible selective androgen receptor modulators and methods of use thereof |
| TW200410921A (en) | 2002-11-25 | 2004-07-01 | Hoffmann La Roche | Mandelic acid derivatives |
| US7217794B2 (en) * | 2003-04-02 | 2007-05-15 | Daiamed, Inc. | Compounds and methods for treatment of thrombosis |
| EP1477167A1 (en) | 2003-05-15 | 2004-11-17 | Pfizer Limited | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists |
| US7268147B2 (en) * | 2003-05-15 | 2007-09-11 | Pfizer Inc | Compounds useful for the treatment of diseases |
| GB0312832D0 (en) * | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
| US7375100B2 (en) | 2003-06-04 | 2008-05-20 | Pfizer Inc | 2-amino-pyridine derivatives useful for the treatment of diseases |
| US7790754B2 (en) | 2003-12-22 | 2010-09-07 | Merck Sharp & Dohme Corp. | Alpha-hydroxy amides as bradykinin antagonists or inverse agonists |
| US7629358B2 (en) | 2004-03-17 | 2009-12-08 | Pfizer Inc | Compounds useful for the treatment of diseases |
| EA200601510A1 (ru) * | 2004-03-17 | 2007-04-27 | Пфайзер Инк. | Производные фенилэтаноламина в качестве бета-2-агонистов |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
-
2005
- 2005-03-06 UA UAA200700165A patent/UA87854C2/ru unknown
- 2005-05-31 MY MYPI20052469A patent/MY147997A/en unknown
- 2005-06-03 NZ NZ551738A patent/NZ551738A/en not_active IP Right Cessation
- 2005-06-03 RU RU2006146678/04A patent/RU2378255C2/ru not_active IP Right Cessation
- 2005-06-03 CN CNA2005800185774A patent/CN1976902A/zh active Pending
- 2005-06-03 BR BRPI0511862-0A patent/BRPI0511862A/pt not_active IP Right Cessation
- 2005-06-03 US US11/145,490 patent/US7268153B2/en not_active Expired - Fee Related
- 2005-06-03 SG SG201100895-0A patent/SG169398A1/en unknown
- 2005-06-03 AT AT05756622T patent/ATE545631T1/de active
- 2005-06-03 CA CA2569124A patent/CA2569124C/en not_active Expired - Fee Related
- 2005-06-03 EP EP05756622A patent/EP1755572B1/en not_active Expired - Lifetime
- 2005-06-03 MX MXPA06014235A patent/MXPA06014235A/es active IP Right Grant
- 2005-06-03 JP JP2007527597A patent/JP4881865B2/ja not_active Expired - Fee Related
- 2005-06-03 PE PE2005000631A patent/PE20060401A1/es not_active Application Discontinuation
- 2005-06-03 TW TW094118475A patent/TW200610755A/zh unknown
- 2005-06-03 US US11/628,685 patent/US7629367B2/en not_active Expired - Fee Related
- 2005-06-03 WO PCT/US2005/019554 patent/WO2005120477A2/en not_active Ceased
- 2005-06-03 AU AU2005251766A patent/AU2005251766B9/en not_active Ceased
- 2005-06-03 AR ARP050102284A patent/AR049140A1/es not_active Application Discontinuation
-
2006
- 2006-11-21 ZA ZA200609673A patent/ZA200609673B/xx unknown
- 2006-12-01 CR CR8777A patent/CR8777A/es not_active Application Discontinuation
- 2006-12-04 EC EC2006007061A patent/ECSP067061A/es unknown
- 2006-12-05 IL IL179843A patent/IL179843A0/en unknown
- 2006-12-25 MA MA29551A patent/MA28677B1/fr unknown
-
2007
- 2007-01-05 NO NO20070085A patent/NO20070085L/no not_active Application Discontinuation
- 2007-03-01 US US11/712,727 patent/US7763659B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008501800A5 (https=) | ||
| RU2006146678A (ru) | N-(2-бензил)-2-фенилбутанамиды в качестве модуляторов рецептора андрогена | |
| RU2345067C2 (ru) | Ингибиторы дпп-iv | |
| JP2009505962A5 (https=) | ||
| RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ | |
| US20060074058A1 (en) | Combination of dpp iv inhibitor and a cardiovascular compound | |
| JP2006525276A5 (https=) | ||
| JP2015528471A5 (https=) | ||
| NZ597241A (en) | Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor | |
| RU2004134564A (ru) | Химические соединения | |
| JP2007519754A5 (https=) | ||
| RU2015117267A (ru) | Замещенные соединения амида | |
| RU2016146826A (ru) | Производные карбонитрилов как селективные модуляторы андрогенового рецептора | |
| JP2004525179A5 (https=) | ||
| JP2016523923A5 (https=) | ||
| EP1621195A3 (en) | The use of pyridinic NK-1 receptor antagonists for the treatment of brain, spinal or nerve injury | |
| JP2008540554A5 (https=) | ||
| UA84146C2 (ru) | Амиды пирролопиридин-2-карбоновой кислоты как ингибиторы гликогенфосфорилазы, способ их получения, фармацевтическая композиция и их применение как терапевтических агентов для лечения заболеваний | |
| JP2012509940A5 (https=) | ||
| PL1735278T3 (pl) | Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne | |
| CA2660529A1 (en) | Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders | |
| EA016687B8 (ru) | Производные циклопропиламида | |
| JP2004509857A5 (https=) | ||
| JP2016514141A5 (https=) | ||
| JP2010533131A5 (https=) |